Home — MRC Weatherall Institute of Molecular Medicine

Beyond cancer dependency maps: the PRECISE vision

Dr Sumana Sharma is one of the founding partners of a major new pan-European initiative that aims to transform how scientists identify and target cancer's weaknesses, moving beyond simply mapping cancer vulnerabilities towards predicting them before they are experimentally tested.

Banner image featuring the words a leader in translating research from bench to clinic, next to an image of a scientist pipetting a pink liquid.

Translating Our Research

Leading research with the aim of improving human health. World-leading research from scientists at the MRC WIMM has been developed into commercial ventures to translate our discoveries into clinics and benefit patients.

The MRC WIMM Green Impact team with the Gold Green Impact award.

MRC WIMM achieves Gold Green Impact award

Congratulations to the Institute's Green Impact team, who achieved Gold in the University of Oxford's 2026 Green Impact awards.

MRC WIMM Research Areas

Research at the MRC WIMM spans 5 core areas.

The image depicts CAR T cells killing malignant bone marrow cells that are expressing mutant CALR, illustrated as a red ‘flag’ on the cell surface.

New personalised therapy targets chronic blood cancer

A new form of CAR T cell therapy has been designed to find and destroy the cancer-driving cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while leaving healthy blood cells unharmed, according to a new study led by UCL and University of Oxford researchers.

Discover. Translate. Advance.

The MRC WIMM's core mission is to improve human health through the pursuit of fundamental research, the development of new technology, and the translation of discoveries to the clinic.

MRC Translational Immune Discovery Unit

Pioneering the future in the study of human immunity to uncover the molecular pathways driving immune-mediated diseases.

Find out more

MRC Molecular Haematology Unit

Understanding how mature blood cells are normally made from stem cells and how this is perturbed in common blood disorders.

Find out more

Centre for Computational Biology

Using computational biology to help understand complex biological systems and combat a range of human diseases.

Find out more

Latest publications

Gut microbiota restricts intestinal lipid uptake via modulation of bile phosphatidylcholine metabolism in mice.

Brunner S. et al, (2026), Nat Microbiol, 11, 2349 - 2364

The Thrombopoietin Receptor S264F Mutant Drives MPN with Marrow Fibrosis Through a Dual Mechanism

MEAD A., (2026), HemaSphere

Resolving hematopoietic stem versus progenitor cell potential in the mouse dorsal aorta by differential Runx1 +110 enhancer activity.

Anselmi G. et al, (2026), Cell Rep, 45

Nucleophagy as an emerging therapeutic vulnerability in cancer.

Tribble S. and Ramadan K., (2026), Autophagy, 1 - 3

The effect of cohesin mutations on HLA-class II expression in the myeloid leukemia of Down syndrome.

Boucher AC. et al, (2026), Leukemia

More Publications

We are sorry, but we are unable to retrieve the events at the moment due to a connection issue. Please try to refresh the page or check back later.

MRC WIMM Interactive Timeline

Accessible Version of Timeline

Cookies on this website

Beyond cancer dependency maps: the PRECISE vision

MRC Translational Immune Discovery Unit

MRC Molecular Haematology Unit

Centre for Computational Biology

Latest publications

Gut microbiota restricts intestinal lipid uptake via modulation of bile phosphatidylcholine metabolism in mice.

The Thrombopoietin Receptor S264F Mutant Drives MPN with Marrow Fibrosis Through a Dual Mechanism

Resolving hematopoietic stem versus progenitor cell potential in the mouse dorsal aorta by differential Runx1 +110 enhancer activity.

Nucleophagy as an emerging therapeutic vulnerability in cancer.

The effect of cohesin mutations on HLA-class II expression in the myeloid leukemia of Down syndrome.

MRC WIMM Interactive Timeline